Five Prime Therapeutics, Inc. (NASDAQ:FPRX) recently saw its volume around 0.68 million shares and on average it trades 0.59 million shares a day. The opening price of $20.27, led it to gain -3.88% to reach $19.8 upon the closing bell.Five Prime Therapeutics, Inc. (FPRX) Analyst Opinion
Five Prime Therapeutics, Inc. has a consensus buy rating from 9 Wall Street analysts, and the number of shares currently sold short amount to at least 10.44% of shares outstanding. The stock sank -1% last month and is down -9.67 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover FPRX having a buy-equivalent rating. Analysts have placed a $59.69 price target on Five Prime Therapeutics, Inc., suggesting a 201.46% gain from recent close. It’s currently trading about -59.48% below its 52-week high.
Five Prime Therapeutics, Inc. (FPRX) surprised the stock market in its last reported earnings when it earned -$1.04 a piece versus the consensus-estimated -$1.31. Its revenue totaled $15.5 million up 86.07% from the previous quarter.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Intraday View
This stock (FPRX) is ahead of its 52-week low with 16.4%. Its last month’s stock price volatility remained 8.13% which for the week stands at 6.76%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.68% and stays -3.99% away from its 50 days moving average. Over the last five days, shares have managed 8.79% gains and now is down -32.01% since hitting its 200-day moving average of $28.95. Five Prime Therapeutics, Inc. (FPRX) has made its way to a 12-month decline of -54.1%.
Turning to Prothena Corporation plc (NASDAQ:PRTA), its shares were trading at $33.84 a gain of $0.78, on the trading floor. The stock, after opening at $32.75, touched a high of $34.43 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Prothena Corporation plc has 5 buy ratings, 1 holds and 0 sells even after the stock tumbled -51.66% from its high of $70.00 to a $1.3 billion market value through last close.
The company’s consensus rating on Reuter’s scale improved from 1.58 to 1.64 during a month. Analysts set a 12-month price target of $72.91 a share. The target implies a 115.46% spike from where the shares are currently trading. Also, the current price highlights a discount of 195.51% to analysts’ high consensus price target.Prothena Corporation plc (NASDAQ:PRTA) Intraday Trading
The counter witnessed a trading volume of 0.39 million shares versus an average volume of 0.48 million shares during last trading session. Its last month’s stock price volatility remained 5.24% which for the week approaches 7.79%. The lowest price the stock reached in the last trading day was $32.05 and compares with the $27.19 52-week low. The stock recovered 24.46% since its low point and has performed -9.74% year-to-date.